Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.54)
# 784
Out of 4,829 analysts
81
Total ratings
52.24%
Success rate
21.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $35.62 | +177.93% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $20.02 | +124.78% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $9.97 | +20.36% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $1.45 | +244.83% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.19 | +267.45% | 2 | Dec 11, 2024 | |
| SVRA Savara | Downgrades: In-Line | $7 → $5 | $2.86 | +74.83% | 3 | Nov 13, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $26.06 | +34.31% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $299.69 | +20.12% | 9 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $251.15 | +3.52% | 1 | Jun 25, 2024 | |
| ANTX AN2 Therapeutics | Maintains: In-Line | $7 → $2 | $1.20 | +66.67% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $7.71 | +328.29% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $39.85 | -4.64% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $438 | $424.99 | +3.06% | 17 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $35.11 | +127.86% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $4.23 | +325.53% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $5.59 | +347.23% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $5.27 | +1,076.47% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.23 | +569.22% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $21.71 | +10.55% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $8.98 | +234.08% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.23 | +209.60% | 1 | Feb 5, 2020 |
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $35.62
Upside: +177.93%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $20.02
Upside: +124.78%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $9.97
Upside: +20.36%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $1.45
Upside: +244.83%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.19
Upside: +267.45%
Savara
Nov 13, 2024
Downgrades: In-Line
Price Target: $7 → $5
Current: $2.86
Upside: +74.83%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $26.06
Upside: +34.31%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $299.69
Upside: +20.12%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $251.15
Upside: +3.52%
AN2 Therapeutics
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.20
Upside: +66.67%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $7.71
Upside: +328.29%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $39.85
Upside: -4.64%
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $424.99
Upside: +3.06%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $35.11
Upside: +127.86%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $4.23
Upside: +325.53%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $5.59
Upside: +347.23%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $5.27
Upside: +1,076.47%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.23
Upside: +569.22%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $21.71
Upside: +10.55%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $8.98
Upside: +234.08%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.23
Upside: +209.60%